BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Research headed by teams at the University of Rochester Center for Translational Medicine and the University of Copenhagen describes for the first time how a spreading wave of disruption and the flow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results